

Developing Feasible Payment Reform Pathways for Antibiotics to Meet the Needs of Providers, Payers, and the Populations They Serve

1201 Pennsylvania Ave, NW, Suite 500, Washington, DC 20004

January 29, 2019

9:00 am – 3:00 pm

Bruce Altevogt

Senior Director of Science Policy, Pfizer Inc.

Deverick Anderson [Remote]

Director, Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University

Helen Boucher

Director, Infectious Diseases Fellowship Program, Tufts Medical Center

Allan Coukell

Senior Director, The Pew Charitable Trusts

Ed Cox

Director, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U.S. Food & Drug Administration

Gregory Daniel

Deputy Director, Duke-Margolis Center for Health Policy

Akin Demehin

Director of Policy, American Hospital Association

Kelly Echevarria

National Clinical Pharmacy Program Manager, Infectious Diseases, VHA Pharmacy Benefits Management, U.S. Department of Veterans Affairs

Gregory Frank

Director, Infectious Disease Policy, Biotechnology Innovation Organization (BIO)

Ray Frost [Remote]

Vice President, Market Access & Health Policy, Melinta Therapeutics

Matthew Goetz

Chief, Infectious Diseases, VA Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs

Bernie Good [Remote]

Senior Medical Director for the Center for Value-Based Pharmacy Initiatives, UPMC

Marianne Hamilton Lopez

Research Director, Duke-Margolis Center for Health Policy

Nicholas Harrison

Senior Research Assistant, Duke-Margolis Center for Health Policy

Chris Henshall

Visiting Fellow, Office of Health Economics (UK)

Amber Jessup

Senior Advisor, Office of The Assistant Secretary for Planning and Evaluation, U.S. Department of Health & Human Services

Amanda Jezek

Senior Vice President, Public Policy and Government, Infectious Diseases Society of America

Jeremy Knox

Policy and Advocacy Lead, Drug-Resistant Infections, Wellcome Trust

Robert Krebs [Remote]

Staff Vice President, Specialty Payment Models,
Anthem, Inc.

Alex Krikorian [Remote]

Vice President, Pharmaceutical Management
and Contracting, Anthem, Inc.

Kerry LaPlante

President, Society for Infectious Diseases
Pharmacists; Director of Research Engagement,
Professor of Pharmacy, University of Rhode
Island

Theresa Madaline

Infectious Disease Specialist, Hospital
Epidemiologist, Montefiore Medical Center

Mark McClellan

Director, Duke-Margolis Center for Health Policy

Karla Miller

Vice President of Pharmacy Services and Clinical
Therapeutics, HCA Healthcare

Gareth Morgan

Senior Vice President Portfolio Management,
Shionogi & Co., Ltd.

Sumathi Nambiar

Director, Division of Anti-Infective Products,
Center for Drug Evaluation and Research, U.S.
Food & Drug Administration

Melinda Neuhauser

Pharmacist and Acute Care Lead, Centers for
Disease Control and Prevention, U.S.
Department of Health & Human Services

Kevin Outterson

Executive Director, CARB-X

David Payne

Vice President Antibacterials, GlaxoSmithKline
plc.

Harold Paz

Executive Vice President & CMO, Aetna Inc.

Manos Perros

President & CEO, Entasis Therapeutics

Chris Regal

Director, Clinical Innovation, America's Health
Insurance Plans

John Rex

CMO; Expert-in-Residence, F2G, Ltd.; Wellcome
Trust

Kevin Ronneberg

Vice President & Associate Medical Director,
Health Initiatives, HealthPartners

Wayne Russell

Vice President, Pharmacy, Premier Inc.

Paul Schaper

Sr. Director, Global Health Policy, Merck &
Company, Inc.

Monika Schneider

Research Associate, Duke-Margolis Center for
Health Policy

Anand Shah

Senior Medical Advisor for Innovation, Centers
for Medicare & Medicaid Services

Surya Singh

President, Singh Healthcare Advisors, LLC

Adrian Towse

Emeritus Director and Senior Research Fellow,
Office of Health Economics (UK)

Blake Wise

CEO, Achaogen, Inc.